Stocks · Health care · Pharmaceutical Preparations

RHYTHM PHARMACEUTICALS, INC.

RYTM Clue Score45
United States Fiscal year ends December CIK 0001649904 Results filed 3 Nov 2026

What the insiders did No buying or selling

By person

15 insiders · 0 transactions
31.1×

David P. Meeker holds 31.1 times base salary in stock. $25.17M of shares against $807.69K in salary for 2025.

Salary from the company's own proxy. The shares are what David P. Meeker last reported holding, valued at $105.19, the price Common Stock was last bought or sold at on the open market here, on 14 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
David P Meeker
President and CEO
—
—
—
239,258
$25.17M
+32.3%
Hunter C Smith
Chief Financial Officer
—
—
—
114,024
$11.99M
+16.4%
Yann Mazabraud
EVP, Head of International
—
—
—
55,655
$5.85M
+59.6%
Pamela J. Cramer
Chief Human Resources Officer
—
—
—
29,376
$3.09M
+117.6%
Edward T Mathers
Director
—
—
—
21,168
$2.23M
+141.3%
Joseph Shulman
Chief Technical Officer
—
—
—
15,915
$1.67M
—
Stuart A Arbuckle
Director
—
—
—
11,712
$1.23M
+290.4%
David W J McGirr
Director
—
—
—
11,712
$1.23M
+290.4%
Christophe Jean
Director
—
—
—
11,712
$1.23M
+290.4%
Lynn A. Tetrault
Director
—
—
—
11,712
$1.23M
+290.4%
Jennifer L Good
Director
—
—
—
11,712
$1.23M
+290.4%
Camille L Bedrosian
Director
—
—
—
7,000
$736.33K
+133.3%
Alastair Garfield
Chief Scientific Officer
—
—
—
2,295
$241.41K
—
Jennifer Kayden Lee
EVP, Head of North America
—
—
—
0
$0.00
−100.0%
Christopher Paul German
Corporate Controller & CAO
—
—
—
0
$0.00
−100.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.